Press Releases

Year

Mar 10 2016

Intec Pharma Completed a Phase I Clinical Trial With Its Third Pipeline Product

JERUSALEM, ISRAEL--(Marketwired - Mar 10, 2016) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has completed a Phase I clinical trial with

Jan 05 2016

Intec Pharma to Present at Biotech Showcase 2016

JERUSALEM, ISRAEL--(Marketwired - Jan 5, 2016) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that its Chief Executive Officer, Zeev Weiss, will

Dec 16 2015

Intec Pharma Further Expands Intellectual Property With a New Patent for the Accordion Pill Zaleplon in Europe

JERUSALEM, ISRAEL--(Marketwired - Dec 16, 2015) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the Company has been informed by the European

Dec 14 2015

Intec Pharma Receives an IRB Approval to Initiate Phase III Clinical Trial of AP - CDLD for the Treatment of Parkinson's Disease

JERUSALEM, ISRAEL--(Marketwired - Dec 14, 2015) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has received a US centralized institutional

Dec 08 2015

Intec Pharma Enters Phase I Clinical Trial With Its Third Pipeline Product

JERUSALEM, ISRAEL--(Marketwired - Dec 8, 2015) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it is entering a Phase I clinical trial with its

Nov 05 2015

Intec Pharma Reports Results for the Third Quarter of 2015

JERUSALEM, ISRAEL--(Marketwired - Nov 5, 2015) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP) ("Intec Pharma" or the "Company"), an Israeli clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced its

Oct 22 2015

Intec Pharma Expands Intellectual Property With a New Patent for the Accordion Pill in Europe

JERUSALEM, ISRAEL--(Marketwired - Oct 22, 2015) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the Company has been informed by the European

Oct 12 2015

Intec Pharma Announces Topline Results of a Food Effect, Pharmacokinetic Study of AP-CDLD 50/500mg for the Treatment of Parkinson's Disease Symptoms

JERUSALEM, ISRAEL--(Marketwired - Oct 12, 2015) - Intec Pharma Ltd . (NASDAQ: NTEC) (TASE: INTC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced results of the food effect study of the Phase 3

Sep 17 2015

Intec Pharma Ltd. Announces Partial Exercise of Underwriters Option to Purchase Additional Ordinary Shares

JERUSALEM, ISRAEL--(Marketwired - Sep 17, 2015) - Intec Pharma Ltd . (the "Company") (NASDAQ: NTEC) (TASE: INTC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the underwriters of its

First page
Previous page
…
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Current page 12

Displaying 111 - 119 of 119